Originally posted on 2/18/2013
Chiasma has turned to ASAP Corporate Member Roche to commercialize its acromegaly and neuroendocrine tumor drug Octreolin
. In exchange for a worldwide exclusive license to Octreolin, Roche will initially pay Chiasma $65 million and possibly up to an additional $530 million with the accomplishment of certain development and commercial milestones. In addition, Chiasma will also get tiered, double-digit royalties if/when Octreolin gets to market.